Full Text Journal Articles by
Author Manu Shankar Hari

Advertisement

Find full text journal articles






Impact of cardiometabolic multimorbidity and ethnicity on cardiovascular/renal complications in patients with COVID-19.

Tom Norris, Cameron Razieh, Francesco Zaccardi, Thomas Yates, Nazrul Islam, Clare L Gillies, Yogini V Chudasama, Alex V Rowlands, Melanie J Davies, Gerry P McCann, Amitava Banerjee, Carolyn S P Lam, Annemarie B Docherty, Peter Jm Openshaw, J Kenneth Baillie, Malcolm Gracie Semple, Claire Alexandra Lawson, Kamlesh Khunti, ,

<h4>Objective</h4>Using a large national database of people hospitalised with COVID-19, we investigated the contribution of cardio-metabolic conditions, multi-morbidity and ethnicity on the risk of in-hospital cardiovascular complications and death.<h4>Methods</h4>A multicentre, prospective cohort study in 302 UK healthcare facilities of adults hospitalised with COVID-19 between 6 February 2020 and 16 March ... Read more >>

Heart (Heart (British Cardiac Society))
[2022, 108(15):1200-1208]

Cited: 0 times

View full text PDF listing >>



Association between tocilizumab, sarilumab and all-cause mortality at 28 days in hospitalised patients with COVID-19: A network meta-analysis.

Peter J Godolphin, David J Fisher, Lindsay R Berry, Lennie P G Derde, Janet V Diaz, Anthony C Gordon, Elizabeth Lorenzi, John C Marshall, Srinivas Murthy, Manu Shankar-Hari, Jonathan A C Sterne, Jayne F Tierney, Claire L Vale,

<h4>Background</h4>A recent prospective meta-analysis demonstrated that interleukin-6 antagonists are associated with lower all-cause mortality in hospitalised patients with COVID-19, compared with usual care or placebo. However, emerging evidence suggests that clinicians are favouring the use of tocilizumab over sarilumab. A new randomised comparison of these agents from the REMAP-CAP trial ... Read more >>

PLoS One (PloS one)
[2022, 17(7):e0270668]

Cited: 0 times

View full text PDF listing >>



Advertisement


Disclaimer

0.8039 s